Project Grant R01CA300721
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded The Washington University Office of Sponsored Research Services $643,286 on August 1, 2026, to investigate DNA methylation epimutations in acute myeloid leukemia under the Cancer Biology Research program (CFDA 93.396). The research investigates allele-specific DNA methylation epimutations as clonal events that arise in normal cells and may be selected for during leukemogenesis. The project uses primary human acute myeloid leukemia samples, normal...
- The National Cancer Institute awarded The Rockefeller University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct genetic research identifying genes that function in RAS-driven cutaneous squamous cell carcinoma. The research addresses how cancer stem cells establish pro-tumorigenic microenvironments. The funded work includes three coordinated aims: identifying which cancer stem cell signature genes persist under different culture conditions;...
- The National Cancer Institute awarded The Washington University $646,785 for a Project Grant (R01CA308205) on August 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into mechanisms supporting growth and survival of tumors driven by constitutively active GNAQ/11 mutations, which occur across a diverse group of rare cancers responsible for approximately thirty percent of annual cancer deaths in the United States. The project investigates how...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded The Washington University $160,093 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate perceptions and informational needs regarding prostate cancer screening among screening-eligible men, with particular attention to racial disparities. The research addresses how men perceive the harms and benefits of prostate-specific antigen (PSA)-based screening, especially in the context of risk-stratified screening...
- The National Cancer Institute awarded The Washington University $637,394 on August 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop positron emission tomography imaging using a radiotracer (64Cu-DOTA-ECL1I) that quantifies C-C motif chemokine receptor 2 (CCR2) expression in head and neck squamous cell carcinoma patients. The project will establish CCR2-PET as a prognostic biomarker to predict tumor activity, disease recurrence, and response to...
- The National Cancer Institute awarded The Washington University $346,506 on August 18, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop novel data science methods for understanding multimorbidity in the context of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) progression. The research aims to synthesize the timing and clustering of multimorbidity diagnoses in relation to body weight change across the disease progression...
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...
- The National Cancer Institute awarded The Washington University $155,500 for research identifying and characterizing mutation-induced alternative splicing events in cancer using multi-omics data, with an award date of June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The project aims to discover mutation-induced alternative splicing events, understand their functional relevance, and identify neoantigens arising from these events to advance cancer immunotherapy. The research...